Guangdong Taienkang

Guangdong Taienkang Pharmaceutical is a comprehensive healthcare company based in China, specializing in the research, development, production, and distribution of pharmaceuticals and medical devices. The company has established a leading position in the male health market, notably through its successful commercialization of Dapoxetine for premature ejaculation. Beyond its proprietary products, Taienkang serves as a major distributor for international pharmaceutical brands, leveraging an extensive sales network across China. Its R&D pipeline includes innovative small molecules like CKBA, which targets autoimmune conditions such as alopecia areata and psoriasis. The company operates multiple GMP-certified manufacturing facilities and is publicly traded on the Shenzhen Stock Exchange. Taienkang continues to expand its portfolio through strategic acquisitions and internal development in dermatology and chronic disease management.